查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1800821

2025-2033年肺動脈高壓藥物市場報告（依藥物類別、給藥途徑、最終用戶和地區分類）

Pulmonary Arterial Hypertension Drugs Market Report by Drug Class, Route of Administration, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球肺動脈高壓 (PAH) 藥物市場規模達80億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到120億美元，2025-2033年期間的複合年成長率 (CAGR) 為4.4%。該市場正在經歷顯著成長，主要得益於標靶療法的進步、PAH盛行率的上升以及公眾意識的提升。不斷擴大的研發投入也為全球市場帶來了正面的前景。

肺動脈高壓藥物市場趨勢：

聯合療法的應用增加

醫生擴大採用聯合療法來提高肺動脈高壓 (PAH) 的治療效果。透過混合使用不同治療類別的藥物，醫生可以針對 PAH 所涉及的多種生物學途徑。這種多層面的方法有助於更有效地控制症狀、減緩疾病進展並改善患者的整體預後。此外，聯合療法可以降低單一藥物的劑量，從而可能減少副作用並提高患者的依從性。由於臨床證據支持其益處，聯合療法正成為 PAH 管理的標準治療方法，推動市場成長和創新。例如，2024 年 3 月，強生公司的 OPSYNVI(R)（馬西替坦和他達拉非）獲得美國 FDA 批准，成為首個針對成人肺動脈高壓 (PAH) 的每日一次單片聯合療法。此項批准基於成功的 3 期 A 階段 DUE 研究，該研究顯示肺血流動力學顯著改善。 OPSYNVI(R) 將兩種成熟的治療方法結合成一片藥片，符合早期合併治療的臨床指引建議。

創新療法日益受到關注

人們對肺動脈高壓 (PAH) 創新療法的日益關注，推動了基因療法和標靶生物製劑的探索，旨在解決該疾病的根本原因。基因療法有望改變與 PAH 相關的遺傳因素，提供長期解決方案，而不僅僅是控制症狀。另一方面，標靶生物製劑則專注於導致疾病進展的特定分子通路，從而實現更個人化、更有效的治療。這些創新方法有望在疾病改良方面取得重大突破，提高 PAH 患者的存活率和整體生活品質。同時，Liquidia Corporation 的 YUTREPIA(TM)（曲前列尼爾）吸入粉劑於 2024 年 8 月獲得美國 FDA 的初步批准，用於治療患有肺動脈高壓 (PAH) 和間質性肺病相關肺動脈高壓 (PH-ILD) 的成人患者。該批准基於 3 期 INSPIRE 試驗，該試驗證明了 YUTREPIA 的安全性和有效性。該公司計劃儘早尋求最終批准，以解決 PAH 和 PH-ILD 患者未滿足的需求。

以病人為中心的照護和數位健康

以患者為中心的護理措施和數位健康工具的整合，透過提高治療依從性和療效，正在影響肺動脈高壓藥物市場的動態。包括行動應用程式和穿戴式裝置在內的數位健康工具能夠持續監測心率和血氧水平等生命徵象。此外，數位平台促進了患者與醫療團隊之間的無縫溝通，從而增強了整體疾病管理。這種整合不僅改善了患者的預後，還使患者能夠積極參與肺動脈高壓（PAH）的管理，從而提高生活品質並提高醫療服務的效率。此外，AJMC 在 2024 年發表的一篇文章指出，孿生技術有可能徹底改變肺動脈高壓 (PH) 的治療。這項技術涉及創建患者的虛擬模型來模擬病情進展並預測治療結果。該研究強調了個人化護理和電腦模擬臨床試驗的潛力，這可以減少傳統試驗所需的時間和成本。數位健康和​​孿生技術的這些進步正在為肺動脈高壓藥物市場創造積極的前景，推動成長並改善患者護理。

肺動脈高壓（PAH）藥物市場細分：

按毒品類別分類：

  • 內皮素受體拮抗劑（ERA）
  • 血管擴張劑
  • 磷酸二酯酶-5（PDE-5）抑制劑
  • 可溶性鳥苷酸環化酶（sGC）促效劑
  • 鈣通道阻斷劑（CCB）
  • 前列環素及其類似物
  • 其他

前列環素和前列環素類似物佔據大部分市場佔有率

前列環素及其類似物在肺動脈高壓 (PAH) 藥物市場佔據主導地位，因其在疾病管理中發揮的關鍵作用而佔據最大的市場佔有率。這些藥物透過擴張血管、降低血管阻力和抑制血小板聚集來發揮作用，從而有效降低肺動脈血壓。它們在改善運動能力和延緩病情進展方面已被證實有效，使其成為 PAH 治療的基石。此外，多種給藥方式，例如靜脈注射、皮下注射和吸入給藥，提高了患者用藥的可近性和便利性。持續的研發進步和新型類似物的推出進一步鞏固了它們的領先地位，推動了肺動脈高壓藥物市場的持續成長。

依給藥途徑分類：

  • 吸入
  • 注射劑
  • 口服

口服給藥佔業界最大佔有率

口服給藥在肺動脈高壓 (PAH) 藥物市場中佔最大佔有率，這得益於其在患者便利性和依從性方面的顯著優勢。口服藥物易於給藥、非侵入性，可在家中服用，無需前往專門的醫療機構，因此在長期治療中極具吸引力。這種易用性提高了患者的依從性，這對於管理像 PAH 這樣的慢性疾病至關重要。此外，藥物製劑的進步提高了口服 PAH 藥物的療效和安全性，從而減少了副作用，並提升了其吸引力。例如，2023 年 12 月，Granules 公司獲得了美國食品藥物管理局 (FDA) 批准其學名藥 Revatio，該藥物用於治療肺動脈高壓 (PAH)。本產品與 Viatris 的西地那非口服混懸液（10 毫克/毫升）具有生物等效性和治療等效性。 Granules 公司表示，該藥物旨在增強 PAH 患者的運動能力並延緩臨床惡化。

按最終用戶分類：

  • 醫院
  • 診所
  • 其他

醫院是肺動脈高壓 (PAH) 藥物市場的主要終端用戶，在疾病的診斷、治療和持續管理中發揮著至關重要的作用。醫院配備先進的診斷工具以及專業的心臟病學和肺病學科室，有助於準確識別 PAH，從而實現及時有效的干涉。醫院管理各種 PAH 藥物，包括先進的生物製劑和聯合療法，確保為患者提供全面的護理。此外，醫院經常參與臨床試驗和研究項目，推動創新和新療法的開發。醫院集中化的基礎設施和多學科協作模式極大地促進了 PAH 藥物在市場上的成長和應用。

診所是肺動脈高壓 (PAH) 藥物市場的重要終端用戶，為 PAH 患者提供便利且持續的照護。這些門診機構提供常規監測、藥物管理和個人化治療方案，從而提高患者的依從性和療效。診所通常與專科醫生合作，使用各種 PAH 藥物（包括口服藥物和注射藥物）提供全面的護理。診所的便利性和本地化佈局使其成為 PAH 等慢性疾病管理的關鍵，確保患者能夠及時調整治療方案。此外，診所還透過拓展 PAH 藥物的分銷管道以及推動患者教育和支持計劃，促進市場成長。

按地區分類：

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

北美領先市場，佔據最大的肺動脈高壓藥物市場佔有率

該報告還對所有主要區域市場進行了全面分析，包括北美（美國和加拿大）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告指出，北美是肺動脈高壓 (PAH) 藥物最大的區域市場。

北美在肺動脈高壓 (PAH) 藥物市場中佔據領先地位，由於幾個關鍵因素佔據了最大的市場佔有率。該地區擁有高度先進的醫療基礎設施和廣泛的專業醫療設施，從而能夠有效診斷和治療 PAH。根據肺動脈高壓藥物市場概況，心血管和呼吸系統疾病的盛行率上升推動了整個地區對 PAH 藥物的需求。此外，北美是大型製藥公司的所在地，這些公司在研發方面投入巨資，促進創新和新療法的推出。有利的監管框架和大量的醫療資金進一步支持了市場成長。此外，對 PAH 的認知和教育程度的提高有助於早期發現和提高治療率，鞏固了北美在市場上的主導地位。例如，2023 年 9 月，范德比爾特大學的研究人員開發了一種新藥 VU6047534，用於治療肺動脈高壓，且不會產生嚴重的神經系統副作用。該藥物標靶作用於心臟和肺部的血清素2B受體，促進器官癒合，並可能逆轉心臟病發作造成的傷害。這種化合物不會進入大腦，代表著一種有望治療肺動脈高壓（PAH）的療法。這項研究由美國國立衛生研究院和范德堡大學資助。

（請注意，這只是關鍵參與者的部分列表，完整列表在報告中提供。）

  • 肺動脈高壓 (PAH) 藥物市場競爭激烈，許多製藥公司競相透過開發創新療法爭奪市場佔有率。市場日益關注先進療法，例如聯合療法和標靶生物製劑，這些療法能夠提高療效並改善患者預後。各公司正大力投資研發，以推出新藥並增強現有療法。定價策略、法規核准和專利到期情況對市場動態產生重大影響。此外，學名藥供應的日益充足也加劇了競爭，而市場領導者則利用強大的分銷網路和臨床試驗結果來保持其領先地位。

本報告回答的關鍵問題

  • 2024 年全球肺動脈高壓 (PAH) 藥物市場規模是多少
  • 2025 年至 2033 年期間全球肺動脈高壓 (PAH) 藥物市場的預期成長率是多少
  • 推動全球肺動脈高壓（PAH）藥物市場的關鍵因素有哪些
  • COVID-19 對全球肺動脈高壓 (PAH) 藥物市場有何影響
  • 根據藥物類別，全球肺動脈高壓 (PAH) 藥物市場如何分類
  • 根據給藥途徑，全球肺動脈高壓 (PAH) 藥物市場分佈如何
  • 全球肺動脈高壓（PAH）藥物市場的主要區域有哪些
  • 全球肺動脈高壓（PAH）藥物市場的主要參與者/公司有哪些

本報告回答的關鍵問題

  • 2024年全球肺動脈高壓 (PAH) 藥物市場規模？ 2025-2033年全球肺動脈高壓 (PAH) 藥物市場的預期成長率為何？
  • 推動全球肺動脈高壓 (PAH) 藥物市場發展的關鍵因素有哪些？
  • COVID-19 對全球肺動脈高壓 (PAH) 藥物市場有何影響？
  • 根據藥物類別，全球肺動脈高壓 (PAH) 藥物市場如何分佈？
  • 根據給藥途徑，全球肺動脈高壓 (PAH) 藥物市場分佈如何？
  • 全球肺動脈高壓 (PAH) 藥物市場的主要區域有哪些？
  • 全球肺動脈高壓 (PAH) 藥物市場的主要參與者/公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球肺動脈高壓（PAH）藥物市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依藥品類別

  • 內皮素受體拮抗劑（ERA）
  • 血管擴張劑
  • 磷酸二酯酶-5（PDE-5）抑制劑
  • 可溶性鳥苷酸環化酶（sGC）促效劑
  • 鈣通道阻斷劑（CCB）
  • 前列環素及其類似物
  • 其他

第7章：市場區隔：依行政途徑

  • 吸入
  • 注射劑
  • 口服

第8章：市場區隔：按最終用戶

  • 醫院
  • 診所
  • 其他

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章：SWOT分析

第 11 章：價值鏈分析

第 12 章：波特五力分析

第13章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Actelion Pharmaceuticals Ltd (Johnson & Johnson)
    • Arena Pharmaceuticals Inc.
    • AstraZeneca PLC
    • Bayer Aktiengesellschaft
    • Daiichi Sankyo Company Limited
    • Gilead Science Inc.
    • GlaxoSmithKline PLC
    • Merck KGaA
    • Novartis International AG
    • Pfizer Inc.
    • United Therapeutics Corporation
Product Code: SR112025A2399

The global pulmonary arterial hypertension (PAH) drugs market size reached USD 8.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 12.0 Billion by 2033, exhibiting a growth rate (CAGR) of 4.4% during 2025-2033. The market is experiencing significant growth mainly driven by advancements in targeted therapies, increasing prevalence of PAH and growing awareness. Expanding research and development (R&D) efforts are also creating a positive outlook for the market further across the world.

Pulmonary Arterial Hypertension Drugs Market Trends:

Increased Use of Combination Therapies

Physicians are increasingly adopting combination therapies to enhance treatment efficacy in Pulmonary Arterial Hypertension (PAH). By prescribing a mix of drugs from different therapeutic classes, they target multiple biological pathways involved in PAH. This multifaceted approach helps to manage symptoms, slow disease progression, and improve overall patient outcomes more effectively. Additionally, combination therapies can allow for lower doses of individual medications, potentially reducing side effects and enhancing patient adherence. As clinical evidence supports their benefits, combination treatments are becoming the standard of care in PAH management, driving market growth and innovation. For instance, in March 2024, Johnson & Johnson's OPSYNVI(R) (macitentan and tadalafil) was approved by the U.S. FDA as the first once-daily single-tablet combination therapy for adults with pulmonary arterial hypertension (PAH). This approval is based on the successful Phase 3 A DUE study, which showed significant pulmonary hemodynamic improvement. OPSYNVI(R) combines two established treatments into a single tablet, aligning with clinical guideline recommendations for early combination therapy.

Rising Focus on Innovative Therapies

The rising focus on innovative therapies in Pulmonary Arterial Hypertension (PAH) is driving the exploration of gene therapies and targeted biologics, which aim to address the root causes of the disease. Gene therapies hold the potential to modify genetic factors involved in PAH, offering a long-term solution rather than just symptom management. Targeted biologics, on the other hand, focus on specific molecular pathways contributing to disease progression, allowing for more personalized and effective treatments. These novel approaches could lead to significant breakthroughs in disease modification, improving survival rates and overall quality of life for PAH patients. In line with this, in August 2024, Liquidia Corporation's YUTREPIA(TM) (treprostinil) inhalation powder received tentative approval from the U.S. FDA to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The approval is based on the Phase 3 INSPIRE trial, which demonstrated the safety and efficacy of YUTREPIA. The company plans to seek final approval at the earliest to address the unmet needs of PAH and PH-ILD patients.

Patient-Centered Care and Digital Health

Patient-centered care initiatives and the integration of digital health tools are influencing the pulmonary arterial hypertension drugs market dynamics by enhancing treatment adherence and outcomes. Digital health tools, including mobile apps and wearable devices, enable continuous monitoring of vital signs such as heart rate and oxygen levels. Additionally, digital platforms facilitate seamless communication between patients and medical teams, enhancing overall disease management. This integration not only improves patient outcomes but also empowers individuals to take an active role in managing their PAH, leading to increased quality of life and more efficient healthcare delivery. Moreover, in an article published by AJMC in 2024, it was suggested that twin technology has the potential to revolutionize pulmonary hypertension (PH) treatment. This technology involves creating virtual models of patients to simulate disease progression and predict treatment outcomes. The study emphasizes the potential for personalized care and in silico clinical trials, which could reduce the time and costs associated with traditional trials. These advancements in digital health and twin technology are creating a positive pulmonary arterial hypertension drugs market outlook, driving growth and improving patient care.

Pulmonary Arterial Hypertension (PAH) Drugs Market Segmentation:

Breakup by Drug Class:

  • Endothelin Receptor Antagonists (ERAs)
  • Vasodilators
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Soluble Guanylate Cyclase (sGC) Stimulators
  • Calcium Channel Blockers (CCBs)
  • Prostacyclin and Prostacyclin Analogs
  • Others

Prostacyclin and Prostacyclin Analogs accounts for the majority of the market share

Prostacyclin and prostacyclin analogs dominate the pulmonary arterial hypertension (PAH) drugs market, accounting for the largest market share due to their critical role in managing the disease. These medications work by dilating blood vessels, reducing vascular resistance, and inhibiting platelet aggregation, which effectively lowers blood pressure in the pulmonary arteries. Their proven efficacy in improving exercise capacity and delaying disease progression makes them a cornerstone of PAH therapy. Additionally, the availability of various administration forms, such as intravenous, subcutaneous, and inhaled options, enhances their accessibility and convenience for patients. Ongoing advancements and the introduction of newer analogs further solidify their leading position, driving sustained pulmonary arterial hypertension drugs market growth.

Breakup by Route of Administration:

  • Inhalation
  • Injectable
  • Oral Administration

Oral Administration holds the largest share of the industry

Oral administration holds the largest share of the pulmonary arterial hypertension (PAH) drugs market due to its significant advantages in patient convenience and adherence. Oral medications are easy to administer, non-invasive, and can be taken at home without the need for specialized medical facilities, making them highly attractive for long-term treatment. This ease of use enhances patient compliance, which is crucial for managing a chronic condition like PAH. Additionally, advancements in pharmaceutical formulations have improved the efficacy and safety profiles of oral PAH drugs, thereby reducing side effects and increasing their appeal. For instance, in December 2023, Granules obtained approval from the U.S. Food and Drug Administration for its generic version of Viatris Specialty's Revatio, a treatment for pulmonary arterial hypertension (PAH). The product is bioequivalent and therapeutically equivalent to Viatris's Sildenafil for oral suspension, 10 mg/ml. Granules stated that the drug is intended to enhance exercise ability and delay clinical worsening in PAH patients.

Breakup by End User:

  • Hospitals
  • Clinics
  • Others

Hospitals are a primary end user in the Pulmonary Arterial Hypertension (PAH) drugs market, playing a crucial role in diagnosis, treatment, and ongoing management of the condition. Equipped with advanced diagnostic tools and specialized cardiology and pulmonology departments, hospitals facilitate the accurate identification of PAH, enabling timely and effective intervention. They administer a wide range of PAH medications, including advanced biologics and combination therapies, ensuring comprehensive patient care. Additionally, hospitals often participate in clinical trials and research initiatives, driving innovation and the development of new treatments. The centralized infrastructure and multidisciplinary approach in hospitals significantly contribute to the growth and adoption of PAH drugs in the market.

Clinics are essential end users in the Pulmonary Arterial Hypertension (PAH) drugs market, providing accessible and continuous care for patients with PAH. These outpatient facilities offer routine monitoring, medication management, and personalized treatment plans, enhancing patient adherence and outcomes. Clinics often collaborate with specialists to deliver comprehensive care, utilizing a variety of PAH drugs, including oral therapies and injectable medications. The convenience and localized presence of clinics make them pivotal in managing chronic conditions like PAH, ensuring that patients receive timely adjustments to their treatment regimens. Additionally, clinics contribute to market growth by increasing the distribution channels for PAH medications and fostering patient education and support initiatives.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest pulmonary arterial hypertension drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for pulmonary arterial hypertension (PAH) drugs.

North America leads the Pulmonary Arterial Hypertension (PAH) drugs market, accounting for the largest market share due to several key factors. The region benefits from a highly advanced healthcare infrastructure and widespread access to specialized medical facilities, enabling effective diagnosis and treatment of PAH. According to pulmonary arterial hypertension drugs market overview, the rising prevalence of cardiovascular and respiratory diseases drives the demand for PAH medications across the region. Additionally, North America is home to major pharmaceutical companies that invest heavily in research and development (R&D), fostering innovation and the introduction of new therapies. Favorable regulatory frameworks and substantial healthcare funding further support market growth. Moreover, increased awareness and education about PAH contribute to the early detection and higher treatment rates, solidifying North America's dominant market position. For instance, in September 2023, researchers at Vanderbilt University developed a new drug, VU6047534, to treat pulmonary arterial hypertension without serious neurological side effects. The drug targets serotonin 2B receptors in the heart and lungs, promoting organ healing and potentially reversing damage from heart attacks. The compound, designed to stay out of the brain, represents a promising therapy for PAH. The research was funded by the National Institutes of Health and Vanderbilt University.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the pulmonary arterial hypertension (PAH) drugs industry include Actelion Pharmaceuticals Ltd (Johnson & Johnson), Arena Pharmaceuticals Inc., AstraZeneca PLC, Bayer Aktiengesellschaft, Daiichi Sankyo Company Limited, Gilead Science Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc. and United Therapeutics Corporation.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • The Pulmonary Arterial Hypertension (PAH) drugs market is highly competitive, with numerous pharmaceutical companies vying for market share through the development of innovative therapies. The market is characterized by a growing focus on advanced treatments, such as combination therapies and targeted biologics, which offer improved efficacy and patient outcomes. Companies are investing heavily in research and development to introduce novel drugs and enhance existing treatments. Pricing strategies, regulatory approvals, and patent expirations significantly influence market dynamics. Additionally, the increasing availability of generics intensifies competition, while market leaders leverage strong distribution networks and clinical trial results to maintain their positions.

Key Questions Answered in This Report

  • 1.What was the size of the global Pulmonary Arterial Hypertension (PAH) drugs market in 2024?
  • 2.What is the expected growth rate of the global Pulmonary Arterial Hypertension (PAH) drugs market during 2025-2033?
  • 3.What are the key factors driving the global Pulmonary Arterial Hypertension (PAH) drugs market?
  • 4.What has been the impact of COVID-19 on the global Pulmonary Arterial Hypertension (PAH) drugs market?
  • 5.What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the drug class?
  • 6.What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the route of administration?
  • 7.What are the key regions in the global Pulmonary Arterial Hypertension (PAH) drugs market?
  • 8.Who are the key players/companies in the global Pulmonary Arterial Hypertension (PAH) drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Endothelin Receptor Antagonists (ERAs)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Vasodilators
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Phosphodiesterase-5 (PDE-5) Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Soluble Guanylate Cyclase (sGC) Stimulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Calcium Channel Blockers (CCBs)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Prostacyclin and Prostacyclin Analogs
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Inhalation
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectable
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Oral Administration
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Actelion Pharmaceuticals Ltd (Johnson & Johnson)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Arena Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 AstraZeneca PLC
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bayer Aktiengesellschaft
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Daiichi Sankyo Company Limited
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Gilead Science Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 GlaxoSmithKline PLC
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Merck KGaA
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Novartis International AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 United Therapeutics Corporation
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Pulmonary Arterial Hypertension Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Drug Class (in %), 2024
  • Figure 4: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Route of Administration (in %), 2024
  • Figure 5: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by End User (in %), 2024
  • Figure 6: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Region (in %), 2024
  • Figure 7: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 8: Global: Pulmonary Arterial Hypertension Drugs (Endothelin Receptor Antagonists - ERAs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Pulmonary Arterial Hypertension Drugs (Endothelin Receptor Antagonists - ERAs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Pulmonary Arterial Hypertension Drugs (Vasodilators) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Pulmonary Arterial Hypertension Drugs (Vasodilators) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Pulmonary Arterial Hypertension Drugs (Phosphodiesterase-5 - PDE-5 Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Pulmonary Arterial Hypertension Drugs (Phosphodiesterase-5 - PDE-5 Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Pulmonary Arterial Hypertension Drugs (Soluble Guanylate Cyclase- sGC Stimulators) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Pulmonary Arterial Hypertension Drugs (Soluble Guanylate Cyclase- sGC Stimulators) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Pulmonary Arterial Hypertension Drugs (Calcium Channel Blockers - CCBs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Pulmonary Arterial Hypertension Drugs (Calcium Channel Blockers - CCBs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Pulmonary Arterial Hypertension Drugs (Prostacyclin and Prostacyclin Analogs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Pulmonary Arterial Hypertension Drugs (Prostacyclin and Prostacyclin Analogs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Pulmonary Arterial Hypertension Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Pulmonary Arterial Hypertension Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Pulmonary Arterial Hypertension Drugs (Inhalation) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Pulmonary Arterial Hypertension Drugs (Inhalation) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Pulmonary Arterial Hypertension Drugs (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Pulmonary Arterial Hypertension Drugs (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Pulmonary Arterial Hypertension Drugs (Oral Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Pulmonary Arterial Hypertension Drugs (Oral Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Pulmonary Arterial Hypertension Drugs (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Pulmonary Arterial Hypertension Drugs (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Pulmonary Arterial Hypertension Drugs (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Pulmonary Arterial Hypertension Drugs (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Pulmonary Arterial Hypertension Drugs (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Pulmonary Arterial Hypertension Drugs (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: North America: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: North America: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: United States: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: United States: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Canada: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Canada: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Asia Pacific: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Asia Pacific: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: China: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: China: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Japan: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Japan: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: India: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: India: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: South Korea: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: South Korea: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Australia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Australia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Indonesia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Indonesia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Europe: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Europe: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Germany: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Germany: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: France: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: France: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: United Kingdom: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: United Kingdom: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Italy: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Italy: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Spain: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Spain: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Russia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Russia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Latin America: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Latin America: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Brazil: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Brazil: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Mexico: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Mexico: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Middle East and Africa: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Middle East and Africa: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Global: Pulmonary Arterial Hypertension Drugs Industry: SWOT Analysis
  • Figure 83: Global: Pulmonary Arterial Hypertension Drugs Industry: Value Chain Analysis
  • Figure 84: Global: Pulmonary Arterial Hypertension Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pulmonary Arterial Hypertension Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 3: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 4: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Pulmonary Arterial Hypertension Drugs Market Structure
  • Table 7: Global: Pulmonary Arterial Hypertension Drugs Market: Key Players